Six Roads to One Target: SIRT1-PGC-1α Convergence Therapy for Long COVID

Background: Long COVID fatigue affects 50–80% of patients and correlates with mitochondrial dysfunction.Previous work established the Toll-NF-κB inflammatory cascade [Paper II] and SSRI serotonergic mechanisms [PaperI]. This paper identifies the upstream regulator linking chronic inflammation to mitochondrial impairment. Discovery: The Sovereign Discovery Engine (3,137 triplets from 98 papers) identified SIRT1-PGC-1α as a criticalconvergence node. Chronic inflammation causes 66% PGC-1α repression, directly impairing mitochondrial biogenesis.Remarkably, six independent interventions—all with quantified efficacy—converge on this same pathway. The Six Roads: (1) NMN supplementation (100-fold SIRT1 increase); (2) EGCG/Green tea (SIRT1/PGC-1αupregulation at 5 mg/kg); (3) Resveratrol (50% PGC-1α restoration); (4) Curcumin (2-fold SIRT1 via AMPK-NAD+); (5) Quercetin (17% mitochondrial biogenesis); (6) Hyperbaric Oxygen Therapy (77% fatigue improvement,SIRT1-mediated). Significance: The convergence of six mechanistically distinct interventions on one pathway is not cherry-picking—itis pattern recognition. All compounds are OTC/supplement-category with established safety profiles. HBOT providesnon-pharmacological cross-validation. This suggests a multi-compound protocol for mitochondrial restoration inLong COVID.